Athenex Revenue and Competitors

Buffalo, NY USA

Location

$312.1M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Athenex's estimated annual revenue is currently $117M per year.(i)
  • Athenex received $100.0M in venture funding in July 2018.
  • Athenex's estimated revenue per employee is $928,968
  • Athenex's total funding is $312.1M.
  • Athenex's current valuation is $120.3M. (January 2022)

Employee Data

  • Athenex has 126 Employees.(i)
  • Athenex grew their employee count by -10% last year.

Athenex's People

NameTitleEmail/Phone
1
CEO & ChairmanReveal Email/Phone
2
Chief Accounting Officer (CAO)Reveal Email/Phone
3
Chief Human Resource Officer responsible for global HR at AthenexI Inc.Reveal Email/Phone
4
Director QualityReveal Email/Phone
5
Director Supply Chain PlanningReveal Email/Phone
6
Director Information TechnologyReveal Email/Phone
7
Regional Director FinanceReveal Email/Phone
8
Manager Legal AffairsReveal Email/Phone
9
Senior Quality Assurance ManagerReveal Email/Phone
10
Sales and Operational PlanningReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.3M617%N/AN/A
#2
$354.3M461-2%$567.1MN/A
#3
$377.1M1876-1%N/AN/A
#4
$7.8M398%N/AN/A
#5
$5.4M270%N/AN/A
#6
$45M2246%N/AN/A
#7
$6.8M34-82%N/AN/A
#8
$9.2M4612%N/AN/A
#9
N/A69446%N/AN/A
#10
$15.5M775%N/AN/A
Add Company

What Is Athenex?

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$312.1M

Total Funding

126

Number of Employees

$117M

Revenue (est)

-10%

Employee Growth %

$120.3M

Valuation

N/A

Accelerator

Athenex News

2022-04-13 - Where Will Athenex Inc (ATNX) Stock Go Next After It Has Fallen 4.82% in a Week?

The market has been down on Athenex Inc (ATNX) stock recently. ATNX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

2022-04-13 - Athenex (NASDAQ:ATNX) Lowered to Hold at Zacks ...

According to Zacks, “Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the...

2022-03-22 - Nasdaq to Athenex: Get stock price above $1 or risk delistment

Buffalo biopharmaceutical company Athenex has had its share of struggles over the last year, and here's another one: The publicly traded...

2021-11-18 - Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Boar ...

2021-11-04 - Athenex Provides Third Quarter 2021 Corporate and Financial Update - Form 8-K

Athenex Provides Third Quarter 2021 Corporate and Financial Update Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M, up 9% year-over-yea ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.7M1266%N/A
#2
$31.6M1269%N/A
#3
$22.9M1270%N/A
#4
$35.1M1308%N/A
#5
$7.5M1308%N/A

Athenex Funding

DateAmountRoundLead InvestorsReference
2018-01-23$UndisclosedUndisclosedDeutsche Bank SecuritiesArticle
2018-01-26$75.4MUndisclosedDeutsche Bank SecuritiesArticle
2018-07-03$100.0MUndisclosedPerceptive AdvisorsArticle